Clinical Trial Update: Study of Guselkumab Versus Placebo for the Treatment of Low Body Surface Area Moderate Plaque Psoriasis [Phase 3]

View source ↗

Summary

Phase 3 study comparing guselkumab versus placebo in patients with low body surface area moderate plaque psoriasis has completed.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Plaque Psoriasis

Drugs mentioned

• TREMFYA (guselkumab)

Snippet

Sponsor: Janssen Research & Development, LLC | Conditions: Moderate Plaque Psoriasis | Phase 3 | Status: COMPLETED